(Q39870984)

15 September 2017

title

The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. (English)

1 reference

15 September 2017

1 reference

1 reference

Kazuma Ohyashiki

1 reference

15 September 2017

Junko H Ohyashiki

1 reference

15 September 2017

Chiaki Kobayashi

1 reference

15 September 2017

Ryoko Hamamura

1 reference

15 September 2017

Seiichi Okabe

1 reference

15 September 2017

Tetsuzo Tauchi

1 reference

15 September 2017

language of work or name

1 reference

9 March 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

100

1 reference

15 September 2017

1 reference

15 September 2017

page(s)

970-977

1 reference

Forging a field: the golden age of iron biology

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Regulation of iron acquisition and storage: consequences for iron-linked disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Transcriptional profiling of Epstein-Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Iron regulates T-lymphocyte sensitivity to the IFN-gamma/STAT1 signaling pathway in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Deferoxamine enhances anti-proliferative effect of interferon-gamma against hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

TSC2: filling the GAP in the mTOR signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Hypoxic condition- and high cell density-induced expression of Redd1 is regulated by activation of hypoxia-inducible factor-1alpha and Sp1 through the phosphatidylinositol 3-kinase/Akt signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Hypoxia signalling through mTOR and the unfolded protein response in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01131.X

10.1111/J.1349-7006.2009.01131.X

21 January 2018

Identifiers

DOI

1 reference

15 September 2017

1 reference